[Endocrine therapy for advanced breast cancer].
Department of Clinical Oncology, Osaka Medical Center for Cancar and Cardiovascular Diseases.
Tetsuhiro
T
Yoshinami
Toshinari
T
Yagi
Makoto
M
Ishitobi
D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D047072:Aromatase Inhibitors / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy*; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D000077267:Fulvestrant; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D017698:Postmenopause; D017697:Premenopause; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D013629:Tamoxifen / Q000008:administration & dosage
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen; D000077267:Fulvestrant; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases